Research

Hormonal

Pharmacological administration of FGF21 improves insulin sensitivity, reduces hepatic triglycerides, and causes weight loss in obese rodents and primates.

Injecting FGF21 in obese animals improves insulin sensitivity, lowers liver fat, and reduces weight by increasing energy expenditure, even without eating less. This suggests a potential therapeutic avenue for metabolic disease.

GoodSupportsHIGH confidence
In this and subsequent studies done in genetic and diet-induced models of obesity, it was shown that FGF21 administration decreased hepatic triglycerides, decreased plasma triglycerides and glucose levels, and caused weight loss by increasing energy expenditure and reducing fat mass without decreasing food intake.
Matthew J. Potthoff et al. · Genes & Development · 2012

Why this rating

Consistent findings across multiple obese animal models and non-human primates.

Source

Endocrine fibroblast growth factors 15/19 and 21: from feast to famine

Matthew J. Potthoff et al. · Genes & Development · 2012

DOI 10.1101/gad.184788.111

narrative_reviewCited 431×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →